agilon health, inc. (NYSE:AGL) Insider Benjamin Kornitzer Sells 5,396 Shares

agilon health, inc. (NYSE:AGLGet Rating) insider Benjamin Kornitzer sold 5,396 shares of the business’s stock in a transaction on Friday, January 20th. The shares were sold at an average price of $19.92, for a total transaction of $107,488.32. Following the sale, the insider now directly owns 10,426 shares of the company’s stock, valued at approximately $207,685.92. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Benjamin Kornitzer also recently made the following trade(s):

  • On Thursday, January 5th, Benjamin Kornitzer sold 2,698 shares of agilon health stock. The shares were sold at an average price of $15.51, for a total transaction of $41,845.98.
  • On Friday, December 16th, Benjamin Kornitzer sold 5,398 shares of agilon health stock. The stock was sold at an average price of $16.82, for a total transaction of $90,794.36.
  • On Monday, December 5th, Benjamin Kornitzer sold 5,398 shares of agilon health stock. The stock was sold at an average price of $17.80, for a total transaction of $96,084.40.

agilon health Stock Up 0.4 %

Shares of NYSE AGL opened at $20.50 on Tuesday. The firm’s 50-day moving average price is $17.43 and its 200-day moving average price is $20.89. The company has a current ratio of 2.48, a quick ratio of 2.48 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $8.44 billion, a price-to-earnings ratio of -78.85 and a beta of 0.80. agilon health, inc. has a 12-month low of $14.36 and a 12-month high of $28.36.

agilon health (NYSE:AGLGet Rating) last announced its earnings results on Thursday, November 3rd. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The business had revenue of $694.86 million for the quarter, compared to analysts’ expectations of $651.24 million. agilon health had a negative net margin of 4.30% and a negative return on equity of 9.31%. On average, equities research analysts anticipate that agilon health, inc. will post -0.21 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

AGL has been the subject of several recent analyst reports. The Goldman Sachs Group dropped their target price on shares of agilon health from $38.00 to $34.00 and set a “buy” rating for the company in a report on Tuesday, November 15th. SVB Leerink dropped their target price on shares of agilon health from $33.00 to $30.00 and set an “outperform” rating for the company in a report on Friday, November 4th. Stifel Nicolaus assumed coverage on shares of agilon health in a research note on Thursday, December 8th. They issued a “buy” rating and a $23.00 price target on the stock. Finally, Wells Fargo & Company decreased their price target on shares of agilon health from $28.00 to $22.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 15th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, agilon health has a consensus rating of “Moderate Buy” and a consensus target price of $28.38.

Institutional Trading of agilon health

Several hedge funds have recently made changes to their positions in the business. Stratos Wealth Partners LTD. raised its position in shares of agilon health by 1.3% during the 2nd quarter. Stratos Wealth Partners LTD. now owns 38,554 shares of the company’s stock valued at $842,000 after buying an additional 500 shares in the last quarter. Handelsbanken Fonder AB grew its holdings in agilon health by 2.1% during the 2nd quarter. Handelsbanken Fonder AB now owns 24,300 shares of the company’s stock valued at $530,000 after purchasing an additional 500 shares during the last quarter. Synovus Financial Corp grew its holdings in agilon health by 5.1% during the 3rd quarter. Synovus Financial Corp now owns 10,671 shares of the company’s stock valued at $251,000 after purchasing an additional 518 shares during the last quarter. Cambridge Investment Research Advisors Inc. grew its holdings in agilon health by 1.6% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 36,478 shares of the company’s stock valued at $796,000 after purchasing an additional 561 shares during the last quarter. Finally, Victory Capital Management Inc. grew its stake in agilon health by 2.6% in the 2nd quarter. Victory Capital Management Inc. now owns 22,855 shares of the company’s stock worth $499,000 after acquiring an additional 584 shares in the last quarter.

About agilon health

(Get Rating)

agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. As of December 31, 2021, it served approximately 238,000 senior members, which included 186,300 medicare advantage members and 51,700 medicare fee-for-service beneficiaries.

Featured Stories

Insider Buying and Selling by Quarter for agilon health (NYSE:AGL)

Receive News & Ratings for agilon health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for agilon health and related companies with MarketBeat.com's FREE daily email newsletter.